Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin
- 29 February 2000
- journal article
- clinical trial
- Published by Elsevier in Clinical Therapeutics
- Vol. 22 (2), 250-264
- https://doi.org/10.1016/s0149-2918(00)88483-0
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- A Controlled Trial of a Critical Pathway for Treatment of Community-Acquired PneumoniaJAMA, 2000
- The cost of treating community-acquired pneumoniaClinical Therapeutics, 1998
- Community-acquired pneumonia: the annual cost to the National Health Service in the UKEuropean Respiratory Journal, 1997
- Clinical prediction rules. A review and suggested modifications of methodological standardsJAMA, 1997
- A Prediction Rule to Identify Low-Risk Patients with Community-Acquired PneumoniaNew England Journal of Medicine, 1997
- Evaluation of a pneumonia practice guideline in an interventional trial.American Journal of Respiratory and Critical Care Medicine, 1996
- Community-Acquired PneumoniaNew England Journal of Medicine, 1995
- Community-Acquired PneumoniaClinical Infectious Diseases, 1994
- Medical Section pf the American Lung Association: Guidelines for the Initial Management of Adults with Community-acquired Pneumonia: Diagnosis, Assessment of Severity, and Initial Antimicrobial TherapyAmerican Review of Respiratory Disease, 1993
- Epidemiology of community-acquired respiratory tract infections in adults: Incidence, etiology, and impactAmerican Journal Of Medicine, 1985